Dr. Chris A. Rhodes
Ph.D. Co-Founder and Chief Technology Officer
Dr. Rhodes is a pharmaceutical technologist with experience in combination product development including formulations and devices for pulmonary inhalation aerosol, nasal spray, transdermal patch, sustained release injection, and oral and ocular delivery systems for biopharmaceutical products and small molecules. He has played a key role in the development of the commercial products, Byetta (exenatide injection, FDA 2005), Lusedra (propofol prodrug, FDA 2008), Bydureon (exenatide extended-release for injectable suspension, FDA 2012), Myalept (metreleptin for severe lypodystrophy, FDA 2014), and Afrezza (insulin inhalation powder, FDA under review 2014).
Dr. Rhodes has been responsible for product development including drug delivery R&D, formulation and process development, clinical supply and manufacturing, analytical and bioanalytical chemistry in companies including SKS Ocular, Amylin Pharmaceuticals, Guilford Pharmaceuticals, and Mannkind Pharmaceuticals.
In addition to leading technical functions, he has also been drug development team leader for drug delivery system and molecule development programs translating them from research through clinical proof-of-concept and readying them for commercialization.
Dr. Rhodes earned his Doctorate degree in physical organic chemistry from UCLA and completed his training with a Post Doctoral position at Yale University. He has a Bachelors degree in chemistry from New York University.